甲磺酸伊马替尼治疗晚期胃肠间质瘤的临床疗效观察

目的：评价甲磺酸伊马替尼治疗晚期胃肠间质瘤的临床疗效和不良反应。方法：2006年10月至20010年10月期间经病理检查确诊的25例晚期胃肠间质瘤患者,使用甲磺酸伊马替尼400mg/日治疗。结果：25例病人均得到随访,完全缓解（CR）0例,部分缓解（PR）13例,疾病稳定（SD）8例,疾病进展（PD）4例,死亡3例。1年存活率100%,2年存活率96%。结论：甲磺酸伊马替尼治疗晚期胃肠间质瘤有较好疗效,能延长患者生命,不良反应轻微,患者能长期耐受。

Clinical Efficacy on Imatinib Mesylate Treatment for Patients with Advanced Gastrointestinal Stromal Tumors

Objective： To evaluate the efficacy and toxicity of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors.Method：A total of 25 cases with advanced gastrointestinal stromal tumors that all proven by pathology were received imatinib mesylate at doses of 400mg/d,from Oct.2006 to Oct.2010.Result： All cases were followed up.None had complete response,13 cases achieved partial response（PR）,8 cases achieved stable disease（SD） and 4 had progression disease（PD）.The overall survival rates at 1 and 2 year was 100% and 96% respectively.25 patients were valuable for the toxicity assessment according to the WHO standard.Conclusion： Imatinib mesylate is a safe and efficacious drug used for the patients with advanced gastrointestinal stromal tumors.Only mild adverse reactions occur and toxicity is acceptable.